Latest filing published 09 Mar 2026 for Jazz Pharmaceuticals plc, €231k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Patricia Carr, listed as senior executive, appears in our data through filings on Jazz Pharmaceuticals plc shares, published by SEC (Form 4). The record holds 25 filings, for trades running from 6 August 2021 to 5 March 2026.
No open-market purchase appears, only 15 sales worth €617k. The rest of the record consists of 8 share grants and 1 option exercise.
The latest filing, published on 9 March 2026, reports a share grant of €231k in Jazz Pharmaceuticals plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 25 declarations